• Further patent application filed for oncology applications
• Patents strengthen the Company’s intellectual property and solidifies its focus in the field of oncology
• Patent filing forms a key part of the Company’s strategy to protect its platform
Melbourne, Australia; 12 April 2017 – Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), is pleased to announce that it has filed a further patent application with IP Australia covering certain novel and innovative applications of its proprietary CymerusTM mesenchymal stem cell (MSC) technology.
The new patent application, which is owned by Cynata, builds on the Company’s robust intellectual property portfolio. The new patent application, should it mature to a granted patent, will provide additional protection for the Company’s unique MSC technology, particularly in fields related to cancer treatment.
Cynata will continue to invest in specific research areas that will underpin its patent portfolio, generating novel and diversified intellectual property and creating more shareholder value.
“This new patent application further strengthens the Company’s intellectual property position and provides additional important commercial exposure to the oncology field. Patents form a key part of our strategy to protect our unique CymerusTM platform and this application is one of a growing portfolio of issued and pending patents in Cynata’s intellectual property estate,” said Dr Ross Macdonald, Cynata’s Managing Director and Chief Executive Officer.
About Cynata Therapeutics (ASX: CYP)
Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical stage stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, CymerusTM, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary CymerusTM technology addresses a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. CymerusTM utilises induced pluripotent stem cells (iPSCs) to produce a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The CymerusTM platform provides a source of MSCs that is independent of donor limitations and provides an “off-the-shelf” stem cell platform for therapeutic product use, with a pharmaceutical product business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.